This study assessed the effects of mumie (shilajit) pre-treatment, a traditional drug which is well known in the ancient medicine of both east and west, on cardiac performance of rats subjected to myocardial injury. Animals were divided into control, M250, and M500 (received mumie at dosages of 250 and 500 mg/kg/day, orally for 7 days, respectively) main groups each consisting of two subgroups—with and without heart injury. On the 6th and 7th days, isoproterenol (ISO) (85 mg/kg i.p.) was injected (s.c.) to half of the animal subgroups to induce myocardial damage. On the 8th day, after hemodynamic parameter recordings, hearts were removed for further evaluation. Mumie pre-treatment had no significant effects on hemodynamic and cardiac indices of normal animals. When the cardiac injury was induced, mumie maintained the ±dp/dt maximum, attenuated the serum cardiac troponin I, and reduced the severity of cardiac lesions. Despite the mild positive effects of mumie on total antioxidant capacity and lipid proxidation index, no significant difference was observed among animal groups. The findings suggest the prominent cardioprotective effect of mumie against destructive effects of ISO. It seems that other mechanisms than reinforcements of antioxidant system are involved in this beneficial effect.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H. M., Burke, M., et al. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No: CD004816. doi:10.1002/14651858.CD004816.pub5.
WHO. (2008). Cardiovascular disease. The World Health report. www.who.int/cardiovasculardiseases/en/. Accessed June 25, 2013.
Luepker, R. V. (2011). Cardiovascular disease: Rise, fall, and future prospects. Annual Review of Public Health, 32, 1–3.
Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., et al. (2010). On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation, 121, e46–e215.
Zhang, X. (2000).World Health Organization (WHO). General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization. http://scholar.google.com/scholar?q=%22+General+guidelines+for+methodologies+on+research+and+evaluation+of+traditional+medicine.+%22&btnG=&hl=en&as_sdt=0%2C5. Accessed June 25, 2013.
Kamboj, V. P. (2000). Herbal medicine. Current Science, 78, 35–39.
Agarwal, S. P., Khanna, R., Karmarkar, R., AnwerMd, Kh, & KharR, K. (2007). Shilajit: A review. Phytotherapy Research, 21, 401–405.
Wilson, E., Rajamanickam, G. V., Dubey, G. P., Klose, P., Musial, F., SahaF, J., et al. (2011). Review on shilajit used in traditional Indian medicine. Journal of Ethnopharmacology, 136, 1–9.
Schepetkin, I., Khlebnikov, A., & Kwon, B. S. (2002). Medical drugs from humus matter: Focus on mumie. Drug Development Research, 57, 140–159.
Srivastava, R. S., Kumar, Y., Singh, S. K., & Ghosal, S. (1988). Shilajit, its source and active principles. In Proceedings of the 16th IUPAC (Chemistry of natural products). Kyoto Japan, pp. 524.
Surapaneni, D. K., Adapa, S. R., Preeti, K., Teja, G. R., Veeraragavan, M., & Krishnamurthy, S. (2012). Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology, 143, 91–99.
Garedew, A., Feist, M., Schmolz, E., & Lamprecht, I. (2004). Thermal analysis of mumiyo, the legendary folk remedy from the Himalaya region. Thermochimica Acta, 417(2), 301–309.
Saqib, M., Kausar, S., & Akhtar, S. (2012). Effect of Shilajit on lipid profile of hyperlipidemic albino rats and comparison with simvastatin. http://pjmhsonline.com/AprJune2012. Accessed June 12, 2013.
Trivedi, N. A., Mazumdar, B., Bhatt, J. D., & Hemavathi, K. G. (2004). Effect of shilajit on blood glucose and lipid profile in alloxan induced diabetic rats. Indian Journal Pharmacology, 36, 373–376.
Gaikwad, N. S., Panat, A. V., Deshpande, M. S., Ramya, K., Khalid, P. U., & Augustine, P. (2012). Effect of shilajit on the heart of Daphnia: A preliminary study. Journal of Ayurveda and Integrative Medicine, 3(1), 3–5.
Frolova, L. N., Kiseleva, T. L., Kolkhir, V. K., Baginskaya, A. I., & Trumpe, T. E. (1998). Antitoxic properties of standard dry mumijo extract. Pharmaceutical Chemistry Journal, 32(4), 26–28.
Velmurugan, C., Vivek, B., Wilson, E., Bharathi, T., & Sundaram, T. (2012). Evaluation of safety profile of black shilajit after 91 days repeated administration in rats. Asian Pacific Journal of Tropical Biomedicine, 2(3), 210–214.
Vivek, B., Wilson, E., Nithya Devi, S. V., Velmurugan, C., & Kannan, M. (2011). Cardioprotective activity of shilajit in isoproterenol-induced myocardial infarction in rats: A biochemical and histopathological evaluation. International Journal Research Photochemistry Pharmacology, 1(1), 28–32.
Rajadurai, M., & Stanely, M. P. (2007). Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology, 230, 178–188.
Joukar, S., Bashiri, H., Dabiri, S., Ghotbi, P., Sarveazad, A., Divsalar, K., et al. (2012). Cardiovascular effects of black tea and nicotine alone or in combination against experimental induced heart injury. Journal of Physiology and Biochemistry, 68(2), 271–279.
Joukar, S., Ghasemipour-Afshar, E., Sheibani, M., Naghsh, N., & Bashiri, A. (2013). Protective effects of saffron (Crocus sativus) against lethal ventricular arrhythmias induced by heart reperfusion in rat: A potential anti-arrhythmic agent. Pharmaceutical Biology, 51(7), 836–843.
Joukar, S., Najafipour, H., Mirzaeipour, F., Nasri, H., Ahmadi, M. Y. H., & Badinloo, M. (2013). Modulatory effect of semelil (angipars™) on isoproterenol induced cardiac injury. Experimental and Clinical Sciences Journal, 12, 122–129.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein estimation with the folin-phenol reagent. The Journal of biological chemistry, 193, 265–275.
Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay of lipid peroxidation in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351–358.
Joukar, S., Shahouzehi, B., Najafipour, H., Gholamhoseinian, A., & Joukar, F. (2012). Ameliorative effect of black tea on nicotine induced cardiovascular pathogenesis in rat. Experimental and Clinical Sciences Journal, 11, 309–317.
O’Brien, P. J., Landt, Y., & Ladenson, J. H. (1997). Differential reactivity of cardiac and skeletal muscle from various species in a cardiac troponin I immunoassay. Clinical Chemistry, 43(12), 2333–2338.
York, M., Scudamore, C., Brady, S., Chen, C., Wilson, S., Curtis, M., et al. (2007). Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat. Toxicologic Pathology, 35, 606–617.
Rona, G., Chappel, C. I., Balazs, T., & Gaudry, R. (1959). An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Archives of Pathology and Laboratory Medicine, 67, 443–455.
Joukar, S., Sheibani, M., & Joukar, F. (2012). Cardiovascular effect of nifedipine in morphine dependent rats: Hemodynamic, histopathological, and biochemical evidence. Croatian Medical Journal, 53(4), 343–349.
Joukar, S., Najafipour, H., Dabiri, S., Sheibani, V., Esmaeili-Mahani, S., Ghotbi, P., et al. (2011). The effect of chronic co-administration of morphine and verapamil on isoproterenol-induced heart injury. Cardiovascular and Hematological Agents in Medicinal Chemistry, 9, 218–224.
Guyton, A. C., & Hall, J. E. (2011). Text book of medical physiology (12th ed., p. 247). Pennsylvania: Saunders.
Dash, B. (1991). Materia medica of ayurveda. New Delhi: B Jain Publishers.
Bhishagratna, K. K. (1998). Susruta Samhita. Vol 2. Varanasi: Chowkhamba Sanskrit Series Office: Varanasi-1: chapter 13.
Ghosal, S. (1989). The facets and facts of shilajit. In P. C. Dandiya & S. B. Vohara (Eds.), Research and development of indigenous drugs (pp. 72–80). New Delhi: Institute of history of medicine and medical research.
Goel, R. K., Banerjee, R. S., & Acharya, S. B. (1990). Antiulcerogenic and antiinflammatory studies with shilajit. Journal of Ethnopharmacology, 29(1), 95–103.
The authors are thankful to the Vice Chancellor of Research, Kerman University of Medical Sciences, for financial support. We also express our gratitude to Ms Nadia Ghazanfari-Moghaddam for her critical proofreading of the manuscript.
About this article
Cite this article
Joukar, S., Najafipour, H., Dabiri, S. et al. Cardioprotective Effect of Mumie (Shilajit) on Experimentally Induced Myocardial Injury. Cardiovasc Toxicol 14, 214–221 (2014). https://doi.org/10.1007/s12012-014-9245-3
- Mumie (shilajit)
- Myocardial injury
- ±dp/dt maximum
- Cardiac troponin I
- Total antioxidant capacity
- Lipid proxidation index